November 15, 2022:
AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM001 for Treatment of Metastatic Colorectal Cancer in Australia
Read more..
November 04, 2022:
AUM Biosciences to Participate in BioCentury-BayHelix East-West BioPharma Summit
Read more..
Oct 20, 2022:
AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V
Read more..
August 18, 2022:
AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene
Read more..
June 07, 2022: AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AUM001 in Colorectal Cancer
May 17, 2022: AUM Biosciences Appoints an industry veteran, Scott Jordan as Head of Corporate Development
May 10, 2022: AUM Biosciences Enters into Collaboration with Roche for Clinical Development of AUM001 in Combination with anti-PD-L1 Therapy in Solid Tumor Indications
May 05, 2022: AUM Biosciences Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate AUM001 in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer
April 19, 2022: AUM Biosciences and HANDOK Presented Phase 1 Data for AUM-601 at ESMO Targeted Anticancer Therapies Congress 2022
Oct 12, 2021: Cancer treatment startup AUM Biosciences raises US$27m in Series A funding
May 11, 2021: AUM Biosciences enters in a Strategic Collaboration with Handok and CMG Pharm to develop ‘CHC2014’, New Pan-TRK Inhibitor for Cancer Treatment
November 18, 2020: AUM Biosciences and Newsoara Biopharma announce a 5-year transformational Strategic Partnership to co-develop and co-discover Next-Generation Cancer Therapeutics
October, 2020: AUM Biosciences Establishes Joint Lab with A*STAR’s Singapore Immunology Network (SIgN) to Accelerate the Development of Targeted Cancer Therapies
January 15, 2020: Cyclica and AUM Biosciences to Partner on Developing Novel Cancer Therapies with Greater Precision and Speed, under Project Nexus
Jul 17, 2019: AUM Biosciences expands pipeline with global license for first-in-class targeted cancer therapy
April 09, 2019: AUM Biosciences awarded Asia-Pacific Biotech Entrepreneurial Company of the Year – 2019
January 21, 2019: AUM Biosciences shares why it is betting on Asia and how it will achieve its vision in feature article on Scrip Pharma Intelligence
January 07, 2019: ET Prime interviews AUM Biosciences on its game-changing Asia-to-Global vision to tackle Asia‘s oncology challenges
December 04, 2018: AUM Biosciences acquires Small Molecule ETC-206 – A Novel, Highly Selective Anti-Cancer Drug
November 13,2018: AUM Biosciences, C-CAMP join hands for cancer therapy
October 09, 2018: AUM Biosciences partners with National Cancer Centre Singapore (NCCS) to develop new cancer drugs
October 02, 2018: AUM Biosciences contributes to the discussion on the rise of medtech companies targeting solutions for Asia-prevalent cancers in a feature article on Bloomberg
August 28, 2018: AUM Biosciences Founder & CEO, Vishal Doshi, meets with premier news outlet, The Edge, to discuss the opportunity for cancer treatments in Asia
August, 2018: AUM Biosciences makes its mark on the Singapore Biotech Ecosystem
June 25, 2018: AUM Biosciences successfully launches to drive commercial innovation in oncology, developing innovative and affordable medicines for Asia